AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 3 - (NewsRx.com & NewsRx.net) -- The incidence of lobular breast cancer has increased steadily from 1987 to 1999, according to a new report.
Previous studies have shown that ever use or current use of combined estrogen and progestin hormone replacement therapy (CHRT) are associated with 2.0-fold to 3.9-fold increased risks of invasive lobular carcinoma (ILC), the second most common type of breast cancer, but that it has little impact on the risk of the most common type of breast cancer, invasive ductal carcinoma (IDC).
Christopher I. Li, MD, PhD, from the Fred Hutchinson Cancer Research Center, Seattle, and colleagues analyzed data from nine cancer registries that identified 190,458 women with invasive breast cancer between 1987 through 1999. Their results were published in the March 19, 2003 issue of the Journal of the American Medical Association.
"Of these cases, 138,625 were IDC (72.8%), 14,486 were ILC (7.6%), and 8860 were invasive mixed ductal-lobular carcinoma [IDLC] (4.7%)," the authors report. "Incidence rates of tumors classified as lobular increased 1.52-fold, and those classified as mixed ductal-lobular increased 1.96-fold; rates of these types combined increased 1.65 ...
Source: HighBeam Research, Incidence of "lobular" disease increasing.(lobular breast cancer)